ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (NAS: IMGN) , a biotechnology company that develops novel anticancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:
Morgan Stanley Global Healthcare Conference
9:10 am ET, September 11 in New York, NY
Stifel Nicolaus 2013 Healthcare Conference
11:30 am ET, September 12 in Boston, MA
The webcasts will be accessible live through the "Investor Information" section of the Company's website, www.immunogen.com; a replay will be available at the same location for approximately a week.
About ImmunoGen, Inc.
ImmunoGen, Inc. develops targeted anticancer therapeutics. The Company's proprietary ADC technology uses a tumor-targeting engineered antibody to deliver one of ImmunoGen's highly potent cancer-cell killing agents specifically to tumor cells. The most advanced compound using ImmunoGen's Targeted Antibody Payload (TAP) technology, Kadcyla®, is marketed in the US by Genentech, a member of the Roche Group, and undergoing regulatory review in the European Union and Japan. ImmunoGen has four wholly owned clinical-stage compounds, with additional compounds in the clinic through partnerships. More information about ImmunoGen can be found at www.immunogen.com.
Kadcyla® is a trademark of Genentech.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
The Yates Network
Barbara Yates, 781-258-6153
KEYWORDS: United States North America Massachusetts New York
The article ImmunoGen, Inc. Announces Webcast of Presentations at Upcoming Investor Conferences originally appeared on Fool.com.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.